ATLANTA--(BUSINESS WIRE)--Dec. 19, 2003--Nova BioGenetics (OTC Bulletin Board: NVBG - News) announces it has sub-registered ANABEC Inc., Kor-Chem, Inc., and WorldCHEM products with the US EPA.
Anabec's product removes stronger categories of mold and bacteria from porous building materials that harbor these strains, addressing the Indoor Air Quality issue. No longer are owners confined to the old protocol which dictated that this matter be removed, an ineffective and costly method. Now materials can actually be "cleaned" and "sealed" with Anabec's patented dyne penetrating surfactant used with an EPA registered antimicrobial shield.
Primarily targeting the industrial and institutional markets, Kor-Chem, Inc. is a specialty chemicals manufacturer of a broad range of products from intermediates and concentrates to solvent based and aqueous fluids in liquid, solid, and granulated grade form. Their 43,000 sq. ft. facility houses production, packaging, and warehousing. Stainless steel reactors/mixing vessels make a wide range of products. Kor-Chem's plant also handles a wide range of viscosities from low viscosity fluid to high viscosity pastes and is configured to safely use solvents, acids, and alkalis.
A chemical manufacturer of commercial cleaning supplies, WorldCHEM, Inc. has devised a "Comprehensive Disease and Odor Control Program." Their products range from EPA registered disinfectants to industrial concentrates, RTU and antimicrobial cleaning compounds. Additionally, WorldCHEM manufactures a complete line of floor care products and offers a "One-Stop" shopping concept to all their customers. WorldCHEM takes pride in their Quality Assurance Program which has earned them a rating of "Excellent" from their National Account Customers.
About Nova BioGenetics:
Nova BioGenetics Inc., ("Nova"), is a biopharmaceuticals company headquartered in Atlanta, Georgia. Nova is engaged in the discovery, development, and commercialization of new therapeutic agents that treat life-threatening infectious diseases. Nova BioGenetics' pipeline, for both FDA and EPA regulatory agencies, is based on patented technology and Nova's own initial bench studies used as a broad base for applications with existing antibiotic compounds. Attaching the patented technology with antibiotic compounds has proven to facilitate potential disruption of bacterial agents thus producing new therapeutic agents to be marketed.
Nova also operates a division responsible for the sale of cutting-edge patented and EPA approved antimicrobials and biocides.
For more information on Nova and its product line, please visit http://www.novabiogenetics.com , Ph.# 770-650-6508, Fax # 770-650-0411. For investor information, contact Todd Smith, Dir. of Investor Relations.
Nova BioGenetics Inc., Atlanta Investor Relations Todd Smith, 770-650-6508
Source: Nova BioGenetics